FSNUY
Fresenius SE & Co. KGaA
OTC Markets OTCPKUSDEQUITY
DELAYED
Last price
13.64
■ 0.00 (0.00%)
MARKET · —
Price
Open
13.60
Prev close
13.64
Day high
13.68
Day low
13.60
Volume
20.87K
Market cap
—
P/E (TTM)
—
52W range
10.33 – 33.93
Trailing performance
Returnvs SPY
1W
-0.44%
+0.9%
1M
+10.89%
+7.2%
3M
+15.20%
+12.1%
6M
-11.43%
-22.5%
YTD
-4.82%
-17.1%
1Y
-1.16%
-21.2%
3Y
+69.02%
-5.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
13.65
-0.04% from price
SMA 20
13.35
+2.20% from price
SMA 50
12.41
+9.87% from price
SMA 100
12.16
+12.19% from price
SMA 200
13.19
+3.45% from price
EMA 12
13.53
+0.82% from price
EMA 26
13.16
+3.68% from price
EMA 50
12.74
+7.09% from price
RSI (14)
66.9
Neutral
MACD (12,26,9)
0.37
Hist -0.03
ATR (14)
0.29
2.14% of price
Realised vol 30D
24.5%
Annualised
Bollinger upper
14.13
20, 2σ
Bollinger lower
12.56
20, 2σ
50 / 200 cross
Death
12.41 vs 13.19
Trend bias
Above 200
+3.45%
Risk profile
Beta vs SPY
0.63
Less volatile than market
Correlation to SPY
0.20
Largely independent
Realised vol 30D
24.5%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-53.7%
Peak to trough
Max drawdown 5Y
-65.1%
Peak to trough
ATR 14
0.29
2.14% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?
Zacks · 11d ago
Fresenius SE & Co KGaA (FSNUY) (Q2 2026) Earnings Call Highlights: Raises Full-Year EPS ...
GuruFocus.com · 17d ago
Fresenius Announces FDA Approval of Rituximab Biosimilar for the U.S. Market
Business Wire · 19d ago
Fresenius: Q2 Earnings Snapshot
Associated Press · 19d ago
Can Volume Growth and RPT Recovery Support DaVita's Q2 Earnings?
Zacks · 19d ago
Fresenius Announces FDA and EMA Acceptance for Review of Vedolizumab Biosimilar Candidate
Business Wire · 22d ago
Fresenius (XTRA:FRE) Stock May Still Be Cheap On Its 66% Run
Simply Wall St. · 23d ago
Chemed (CHE) Tops Q2 Earnings and Revenue Estimates
Zacks · 25d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.